

PRESENTATION

 $oldsymbol{Mucospel}^{\otimes}$ Syrup: Each 5 ml syrup contains Bromhexine Hyrdochloride BP 4 mg.

PHARMACOLOGY

Bromhexine hydrochloride is rapidly absorbed from the gastrointestinal tract. It is widely distributed to body tissues and is highly bound to plasma proteins. About 85 to 90% of a dose is excreted in the urine mainly as metabolites. It has a terminal elimination half-life of up to about 12 hours.

Mechanism of Action:

Bromhexine is an oral mucolytic agent with a low level of associated toxicity. It acts on the mucus at the formative stages in the glands, within the mucus-secreting cells. Bromhexine disrupts the structure of acid mucopolysaccharide fibres in mucoid sputum and produces less viscous mucus, which is easier to expectorate.

INDICATION

Mucospel® is indicated in the treatment of respiratory disorders associated with viscid or excessive mucus or productive cough. This include:

- Tracheobronchitis
- Bronchitic with emphysema
- Bronchiectasis
- Bronchitis with bronchospasm
- Chronic inflammatory pulmonary conditions
- Pneumoconiosis

DOSAGE AND ADMINISTRATION

Mucospel Syrup:

Adults and Children over 10 years: 2 to 4 teaspoonfuls (8 -16 mg), 3 times daily. Initially 4 teaspoonfuls, 3 times daily, then as required.

Children 5 - 10 years: 1 teaspoonful (4 mg), 3 times daily Children 2 - 5 years: ½ teaspoonful (2 mg), 3 times daily Children below 2 years: ¼ teaspoonful (1 mg), 3 times daily.

SIDE EFFECTS

Gastrointestinal side effects may occur occasionally with bromhexine and a transient rise in serum aminotransferase values has been reported. Other reported adverse effects include headache, vertigo (dizziness), sweating and allergic reactions.

CONTRAINDICATION

Bromhexine is contraindicated for use in patients with known hypersensitivity or idiosyncratic reaction to bromhexine

hydrochloride (or any of the other ingredients in the product).

PRECAUTION

Since mucolytics may disrupt the gastric mucosal barrier, bromhexine should be used with caution in patients with a history of gastric ulceration. Clearance of bromhexine or its metabolites may be reduced in patients with severe hepatic or renal impairment.

USE IN PREGNANCY AND LACTATION

Category B: Bromhexine has been taken by a large number of pregnant women and women of child bearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed.

It is not known whether bromhexine is excreted in breast milk or whether it has a harmful effect on the breastfeeding infant. Therefore it is not recommended for breastfeeding mothers unless the potential benefits to the patient are weighed against the possible risk to the infant.

STORAGE CONDITION

Store at a cool and dry place. Protect from light and moisture. Keep the medicine out of the reach of children.

HOW SUPPLIED

Mucospel® Syrup: Each PET bottle contains 100 ml syrup and a measuring cup.

Manufactured by

SQUARE
PHARMACEUTICALS LTD.

Pabna, Bangladesh

R Registered Trade Mark